Core Insights - CytomX Therapeutics is advancing its CX-2051 Phase 1 study for colorectal cancer (CRC) with 73 patients enrolled and aims to provide a data update in Q1 2026 [1][2][6] - Patient safety is prioritized as the study continues with dosing across all expansion doses [2][6] Company Overview - CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing conditionally activated, masked biologics for cancer treatment [4] - The company utilizes its PROBODY therapeutic platform to create localized therapies, including antibody-drug conjugates (ADCs) and immune modulators [4] - Current clinical-stage pipeline includes CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM), and CX-801, a masked interferon alpha-2b PROBODY cytokine [4] CX-2051 Program Status - The CX-2051 study has enrolled approximately 20 patients at each of the three expansion doses: 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg, administered every three weeks [6] - A serious adverse event (Grade 5 treatment-related acute kidney injury) was reported, but the study continues with support from the Safety Review Committee [6] Strategic Collaborations - CytomX has established partnerships with leading oncology companies, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [4]